• linkedin
  • Increase Font
  • Sharebar

    Study: Active surveillance uptake remains low

    Surveillance use in low-risk prostate Ca varies significantly across facilities


    Facility volume, type linked with AS

    Factors associated with receipt of AS were facility volume and facility type. The odds ratio of receipt of AS was 3.5 (95% CI: 1.84-6.68; p<.001) in facilities with the highest volume compared with lowest volume. The highest likelihood of receipt of AS was in community cancer programs and academic institutions. Relative to patients treated at comprehensive community cancer centers, patients treated at community cancer programs had an OR of 2.74 (95% CI: 1.94-3.88; p<.001) and those treated at academic institutions had an OR of 2.50 (95% CI: 1.77-3.54; p<.001).

    “There are some high-volume facilities that almost never treat patient with AS,” Dr. Löppenberg said.

    Adjusted for all factors, the mean probability of receiving AS was 0.033 (95% CI: 0.023-0.256).

    Read: Genomic testing linked to higher surveillance uptake

    The overall model explained 40% of the variation in receipt of AS. Of the unexplained variation, 35% could be attributed to a single facility, he said.

    “Policies to achieve more consistent and higher rates of AS, when appropriate, should be a priority of professional societies and patient advocacy groups,” Dr. Löppenberg said.

    The National Cancer Data Base captures about 70% of all newly diagnosed prostate cancer in the United States, he explained.

    “The NCDB estimates that approximately 50% of all newly diagnosed prostate cancers are within their database,” he said. “So we think that quite a large proportion of these patients do not receive AS.”

    More from Urology Times:

    CCP score further risk stratifies surveillance candidates

    Current prostate Ca guidelines miss germline variants

    RT-ADT combo may boost pN1 prostate cancer survival

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • [email protected]
      This would be a meaningful MIPS question. If we're worried about still getting bone scans on very low risk prostate cancer we're all in trouble. Roscoe Nelson